Information acquisition differences between experienced and novice time trial cyclists

Purpose: To use eye-tracking technology to directly compare information acquisition behavior of experienced and novice cyclists during a self-paced 10 mile (16.1 km) time-trial. Method: Two groups of novice (N=10) and experienced cyclists (N=10) performed a 10-mile self-paced time-trial (TT) on two separate occasions during which a number of feedback variables (speed, distance, power output, cadence, heart rate, and time) were projected within their view. A large RPE scale was also presented next to the projected information and participants. Participants were fitted with a head-mounted eye32 tracker and heart rate monitor. Results: Experienced cyclists performed both time-trials quicker than novices (F1,18=6.8, P=.018) during which they primarily looked at speed (9 of 10 participants) whereas novices primarily looked at distance (6 of 10 participants). Experienced cyclists looked at primary information for longer than novices across the whole time-trial (24.5±4.2% vs. 34.2±6.1%, t18=4.2, P<0.001) and less frequently than novices during the last quarter of the time-trial (49±19 vs. 80±32, t18=-2.6, P=0.009). The most common combination of primary and secondary information looked at by experienced cyclists was speed and distance respectively. Looking at ten different primary-secondary feedback permutations, the novices were less consistent than the experienced cyclists in their information acquisition behavior. Conclusion: This study challenges the importance placed on knowledge of the endpoint to pacing in previous models, especially for experienced cyclists for whom distance feedback was looked at secondary to, but in conjunction with, information about speed. Novice cyclists have a greater dependence upon distance feedback, which they look at for shorter and more frequent periods of time than the experienced cyclists. Experienced cyclists are more selective and consistent in attention to feedback during time-trial cycling

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Frequency of Antineutrophil Cytoplasmic Antibodies (ANCA) in Some Autoimmune Diseases

Anti-Neutrophil Cytoplasmic Antibodies (ANCA) are a heterogeneous group of autoantibodies with a broad spectrum of clinically associated diseases. The diagnostic value is established for Proteinase 3 (PR3)-ANCA as well as Myeloperoxidase (MPO)-ANCA. To estimate the frequency of anti-neutrophile cytoplasmic antibodies (ANCA) in sera from a group of Iraqi patients with some autoimmune diseases compared with a healthy control group. Serum samples were collected from one hundred patient, 47 males and 53 females; with age range of 16-70 years; 20 specimens from patients with systemic lupus erythematosus (SLE), 30 from patients with ulcerative colitis (UC), and 50 from patients with rheumatoid arthritis (RA). A group of 40 apparently healthy blood donors was included as controls. ANCA were checked using enzyme-linked immunosorbent assay (ELISA). Positive ANCA was detected in sera of 18 (18%) patients with autoimmune disorders. Anti-PR3 was detected in 6 (12%) patients with RA, and in 4(13.4%) patients with UC. Anti-MPO was detected in 3(6%) patients with RA and in 5(16.6%) patients with UC. All serum samples of patients with SLE showed negative ANCA. There were no ANCAs detected in sera from healthy individuals. Mean of serum anti-PR3 (U/ml) among the studied groups was 2.057 in RA, 2.209 in SLE, and 2.283 in UC, and 1.739 in control group. Statistical analysis revealed that differences in the anti-PR3 between RA, UC and controls were highly significant (P > 0.01), whereas just significant with SLE (P> 0.05). Mean of serum of anti-MPO (U/ml) among the studied groups was 0.711 in RA, 0.695 in SLE, and 1.170 in UC, and 0.652 in control group. Statistical analysis revealed that the differences in the anti-MPO between RA and SLE, controls were non significant (P 0.01).It was concluded that ANCA markers might play a role in the inflammatory process and they are important factors for the clinical course, and prognosis in the patients with autoimmunity. However, ANCA in autoimmune disorders must be interpreted cautiously with particular attention paid to laboratory technique, the size, age and genetic background of the populations studied. Key words: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Anti-neutrophile Cytoplasmic Antibodies (ANCA).